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Isolated complex III (cIII) deﬁciency is a rare biochemical ﬁnding in mitochondrial disor-
ders, mainly associated with mutations in mitochondrial DNA MTCYB gene, encoding
cytochrome b, or in assembly factor genes (BCS1L,TTC19, UQCC2, and LYRM7 ), whereas
mutations in nuclear genes encoding cIII structural subunits are extremely infrequent.We
report here a patient, a 9 year old female born from ﬁrst cousin related parents, with
normal development till 18 months when she showed unsteady gait with frequent falling
down, cognitive, and speech worsening. Her course deteriorated progressively. Brain
MRI showed cerebellar vermis hypoplasia and bilateral lentiform nucleus high signal
lesions. Now she is bed ridden with tetraparesis and severely impaired cognitive and
language functions. Biochemical analysis revealed isolated cIII deﬁciency in muscle, and
impaired respiration in ﬁbroblasts. We identiﬁed a novel homozygous rearrangement in
TTC19 (c.213_229dup), resulting in frameshift with creation of a premature termination
codon (p.Gln77Argfs*30). Western blot analysis demonstrated the absence of TTC19
protein in patient’s ﬁbroblasts, while Blue-Native Gel Electrophoresis analysis revealed the
presence of cIII-speciﬁc assembly intermediates. Mutations in TTC19 have been rarely
associated with mitochondrial disease to date, being described in about ten patients
with heterogeneous clinical presentations, ranging from early onset encephalomyopathy
to adult forms with cerebellar ataxia. Contrariwise, the biochemical defect was a
common hallmark in TTC19 mutant patients, conﬁrming the importance of TTC19 in cIII
assembly/stability.Therefore, we suggest extending theTTC19 mutational screening to all
patients with cIII deﬁciency, independently from their phenotypes.
Keywords: TTC19, complex III deficiency, novel mutation, mitochondrial diseases, bilateral basal ganglia lesions,
encephalomyopathy
INTRODUCTION
Mitochondrial respiratory chain consists of ﬁve enzymatic
multi-heteromeric complexes embedded in the inner mem-
brane of mitochondria. Complex III (cIII) is responsible
for the electron transfer from reduced Coenzyme Q to
cytochrome c. It consists of 11 subunits, one of which
(cytochrome b, cyt b) is encoded by the mitochondrial
DNA (mtDNA), whereas the others are encoded by nuclear
genes, synthesized in the cytosol and imported into mitochon-
dria (Iwata and Nakai, 1998). cIII assembly is a step-wise
process, requiring the action of dedicated assembly factors
(Ghezzi and Zeviani, 2012).
About half of mitochondrial disorders with cIII deﬁciency
(MIM124000) remains without a molecular diagnosis and
this is principally due to the incomplete understanding of
cIII assembly and to a wide phenotypic heterogeneity of
patients. Isolated cIII deﬁciency is mainly associated with
mutations in mtDNA MTCYB gene (MIM516020), encod-
ing cyt b, or in assembly factor genes (BCS1L–MIM603647,
TTC19–MIM613814, UQCC2–MIM614461, andLYRM7–MIM61
5831), whereas mutations in nuclear genes coding cIII struc-
tural subunits are extremely infrequent. Most of the MTCYB
mutations are sporadic and cause a mitochondrial myopathy.
cIII disorders due to nuclear mutations have usually an auto-
somal recessive inheritance pattern with onset at birth. The
peculiar clinical features are lactic acidosis, hypotonia, failure
to thrive, delayed psychomotor development, encephalopathy
(Ghezzi and Zeviani, 2012; Invernizzi et al., 2013); in some
patients visceral involvement as hepatopathy and tubulopathy has
been reported (de Lonlay et al., 2001; De Meirleir et al., 2003;
Tucker et al., 2013).
TTC19 is a mitochondrial protein, embedded in the inner
mitochondrial membrane, which has been proposed to have a
role in an early step of cIII assembly. Mutations in TTC19 were
described for the ﬁrst time in three Italian individuals from two
unrelated families with young-onset characterized by slowly pro-
gressive encephalopathy and isolated cIII deﬁciency, and in a
fourth Italian individual with an adult-onset characterized by
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subacute, rapidly progressive neurological failure and isolated cIII
deﬁciency (Ghezzi et al., 2011). After this paper few other patients
have been reported with TTC19 mutations, all presenting iso-
lated cIII deﬁciency, but various clinical-radiological phenotypes:
severe olivo–ponto–cerebellar atrophy and progressive psychosis
in Portuguese siblings from a consanguineous family (Nogueira
et al., 2013), Leigh syndrome in a Hispanic 4 year-old boy (Atwal,
2013), or adult-onset spinocerebellar ataxia in a Japanese woman
(Morino et al., 2014).
Here, we report a novel deleterious mutation in TTC19 in a




We describe a 9 year-old female child from Palestinian related
parents (ﬁrst cousins) of Muslim origin. Pregnancy and deliv-
ery were unremarkable; the baby weighted 3 kg at birth. She was
referred to have had normal development until 18th month of
age, when parents started noticing unsteady gait with frequent
falling. These symptoms were not cared of until 7 years of age,
when learning difﬁculties became evident: she showed attention
and memory deﬁcit with difﬁculties manipulating objects and
dysgraphia. Behavioral alterations were also noted, with abnor-
mal sleep pattern characterized by night terrors and purposeless
movements.
At ﬁrst evaluation (at 7 years of age) she weighted 18 kg
(5th centile), her height was 116 cm (25th centile), and her
head circumference was normal (51.5 cm). Physical examination
revealed neither facial dysmorphisms nor organomegaly. Neuro-
logical examination showed normal eye movements, cock-wheel
rigidity of upper limbs with normal tone of legs, unsteady wide-
based gait. Deep tendon reﬂexeswere normal. Her blood andurine
work including lactate, ammonia, CPK, hepatic assessment, urine
organic acids, and plasma amino acid chromatography did not
show any alteration.
Brain MRI showed mild cerebellar vermis atrophy and sym-
metrical bilateral hyperintensity of lentiform nucleus in T2
FIGURE 1 | Brain MRI. Axial T2-weighted (A) and FLAIR (B) images of the
patient, taken at 7 years of age. Note the hyperintense signals due to
gliosis (A) and the cavitations (B) in the lentiform nuclei.
(Figure 1A) and diffusion weighted images, with cavitated
aspects in FLAIR sequence, as seen in necrotic brain lesions
(Figure 1B).
Her symptoms deteriorated progressively leading to tetrapare-
sis and severe impairment of cognitive and language perfor-
mances. She is now, at 9 years of age, bed-ridden. The parents
signed an informed consent, approved by the ethics commit-
tee at Makassed Hospital, in agreement with the Declaration of
Helsinki.
BIOCHEMICAL ANALYSIS
Measurement of the mitochondrial respiratory chain enzymes
activity was performed by standard spectrophotometric
techniques in muscle homogenate and in digitonin-treated cul-
tures skin ﬁbroblasts grown either in glucose-rich or in 5 mM
galactose, glucose-free DMEM media for 48 h. (Bugiani et al.,
2004). Oxygen consumption rate was measured using a SeaHorse
FX-96 apparatus (Bioscience) in ﬁbroblasts grown in glucose-
rich DMEM medium and maximal respiration rate (MRR) was
calculated as previously described (Invernizzi et al., 2012).
MOLECULAR ANALYSIS
Total genomic DNA was extracted by standard methods from
peripheral blood lymphocytes. Whole-exome sequencing (WES),
using a commercial capture kit (Agilent SureSelect Human All
Exon 50 Mb Kit), was performed as previously reported (Edvard-
son et al., 2013). Sanger sequencing of exon two of TTC19 was
performed in Pt and her parents, using the following oligonu-
cleotides: forward (Fw) TCCTGAGCTGGAGCCTGG and reverse
(Rc) AAAGCCTGGATGGATTCCAAT.
Total RNA was extracted from culture ﬁbroblasts by RNeasy
Mini Kit (QIAGEN), then 200 ng of RNA were retro-transcribed
using GoScript Reverse Transcriptase (Promega), following man-
ufacturer’s recommendations. The expression levels of TTC19 and
the housekeeping gene GAPDH, used for normalization, were
analyzed by GoTaq qPCR Master Mix (Promega).
Primer sequences: for TTC19, Fw: CAAGCTGACCCCG-
TATAAATGC and Rc: AACAAGAAGGCCATCACTTACACTT; for
GAPDH, Fw: CTCTGCTCCTCCTGTTCGAC and Rc: ACGAC-
CAAATCCGTTGA.
IMMUNOBLOT ANALYSIS
To obtain a mitochondrial enriched fraction we digitonized
culture ﬁbroblasts. Brieﬂy, approximately 2 × 106 cells were
pelleted, washed twice with PBS and incubated on ice with
buffer A (MOPS 20 mM, sucrose 0,25 M, pH 7.4) and digi-
tonin 100 μg/ml for 5 min. Then sample was centrifuged at
5,000 × g for 3 min and pellet was incubated on ice with buffer
B (MOPS tampon 20 mM, sucrose 0.25 M, EDTA Na4 1 mM,
pH 7.4) for 5 min, centrifuged at 10,000 × g for 3 min and
the pellet obtained was used for western blot analysis. 50 μg of
digitonin-treated culture ﬁbroblasts from patient and controls
were separated by 12% SDS-polyacrylamide gels and trans-
ferred to nitrocellulose membrane and incubated with antibodies
against TTC19 (Sigma) and SDHA (Invitrogen). Immunoblot
analysis was performed with the ECL-chemiluminescence kit
(Amersham).
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BLUE NATIVE GEL ELECTROPHORESIS
About 106 culture ﬁbroblasts from patient and controls were
pelleted and incubated on ice with digitonin 0.4% for 10 min.
Then samples were washed twice with PBS and incubated on
ice with dodecylmaltoside 1% and NativePAGE Sample Buffer
1X (Invitrogen) for 15 min. After the incubation, samples were
centrifuged at 20,000 × g for 30 min and the supernatants were
measured out. Then 10 μg of supernatants plus the NativePAGE
0,25% G-250 sample additive (Invitrogen) were separated by
3–12% gradient NativePAGE Novex Bis-Tris Gels (Invitrogen) and
transferred to nitrocellulose membranes and incubated with anti-




Spectrophotometric measurement of the activities of mitochon-
drial respiratory chain (MRC) complexes showed isolated,marked
reduction of III in Pt muscle (28% of control mean, after
normalization for the activity of citrate synthase, CS; Table 1).
A decrease in cIII/CS was also observed in Pt ﬁbroblasts grown in
either glucose or galactose medium (55 and 52% of the control
mean, respectively; Figure 2A). Accordingly, MRR of Pt ﬁbrob-
lasts was reduced compared to control cells, indicating reduced
electron ﬂow through the MRC (Figure 2B).
GENETIC STUDIES
We performed whole exome sequencing on genomic DNA
from Pt. After ﬁltering steps to exclude common SNPs (fre-
quency> 0.5%), we searched for homozygous variants, according
to a predicted recessive mode of inheritance and because of the
parents’ consanguinity. This strategy revealed the presence of
a homozygous missense variant in TTC19. The TTC19 open
reading frame contains two putative start codons, corresponding
to methionines M1 (NM_017775.2) and M122 (NM_017775.3),
but the 380-aminoacids protein, starting from the M122, has
Table 1 | Biochemical analysis of MRC complex activities in muscle homogenate.
Muscle CSa cIb cIIb cIIIa cIVc cVb
Ct value 1 ± 0.5 98 ± 46 80 ± 44 1.1 ± 0.5 9.2 ± 5.1 0.450 ± 0.229
Pt 1.3 144 (113%) 40 (84%) 0.4 (28%) 14 (117%) 0.631 (108%)
Enzyme activities are expressed as: aμmol/min/mg; bnmol/min/mg; cK/mg. In brackets the enzymatic activities normalized for citrate synthase activity (CS) and
expressed as percentage of the mean control value. The values out of the control range are reported in bold.
FIGURE 2 | Biochemical and genetic studies. (A) Complex III (cIII) activity
in patient (Pt) and control (Ct) ﬁbroblasts grown in either glucose-rich or in
5 mM galactose, glucose free medium for 48 h. The speciﬁc activities
were normalized for citrate synthase activity. Bars represent SD. Pt vs Ct:
p < 0.005 (in glucose), p < 0.001 (in galactose). The p-values were
obtained by unpaired, two-tail Student’s test. (B) Maximal respiration rate
(MRR) measurements performed in Pt and Ct ﬁbroblasts, grown in
glucose medium. MRR values are expressed as pMolesO2/min/cells. Bars
represent SD. Pt vs Ct: p < 0.001 (p-value obtained by unpaired, two tail
Student’s t -test). (C) Electropherogram of the TTC19 genomic region
including the homozygous 17bp duplication (c.213_229dup) in the patient
(Pt, lower panel) and in a control subject (Ct, upper panel). (D) Pedigree of
the family. dup: allele harboring the c.213_229duplication; wt: allele
harboring the wild-type TTC19 sequence.
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been proposed to be the most likely human TTC19 protein
(Ghezzi et al., 2011) and now the only one reported in most of
the protein databases. This is corroborated from the fact that
the region upstream the M122 is not conserved among species.
The variant found in Pt, predicted to cause the c.220G > C,
p.Arg74His change in the longer isoform, was in fact localized
in an untranslated region (c.–239G > C) upstream the AUG
initiation codon of the standard TTC19 isoform. To exclude
a deleterious effect of this variant on the stability of TTC19
mRNA, we quantiﬁed the levels of TTC19 transcript in Pt ﬁbrob-
lasts that were comparable to control subjects. Next, we checked
the coverage of all TTC19 exons obtained by the exome anal-
ysis to identify any missing region: we noticed that exon two
was poorly captured by the kit used for WES. We performed
Sanger’s sequencing of exon two and identiﬁed a homozygous
17 bp duplication (c.213_229dup) in Pt (Figure 2C), that was
present in heterozygous state in her parents (Figure 2D). This
rearrangement is predicted to cause a frame-shift with the cre-
ation of a premature termination codon (p.Gln77Argfs∗30). The
analysis of the TTC19 mRNA obtained from Pt ﬁbroblasts con-
ﬁrmed the presence of the 17 extra bases in the full-length
transcript, without evidence of any further aberrant transcript
(not shown) suggesting no inﬂuence of the duplication in the
splicing processes.
ANALYSES OF TTC19 AND cIII ASSEMBLY
As expected from the predicted consequence of the mutation on
the protein, immunoblot analysis on digitonin-treated ﬁbroblasts
fromPt showed the absenceof thematureTTC19 wild-type species
(Figure 3A). To evaluate if the absence of TTC19 protein alters
the assembly and stability of cIII we performed Blue-Native Elec-
trophoresis analysis. No muscle was available for this assay, hence
we used Pt ﬁbroblasts. We did not observe a clear reduction in
the amount of cIII holocomplex, but we detect the presence of
cIII-speciﬁc assembly intermediates containing UQCRC1 subunit
(Figure 3B), similar to those previously reported in muscle from
mutant TTC19 subjects (Ghezzi et al., 2011).
DISCUSSION
One of themajor challenges inmitochondrialmedicine is to estab-
lish a correlation between disease phenotype and genotype, and
then to understand the biological bases of these links. It is not rare
to have multiple clinical presentations associated with mutations
in the same gene. This happens also for cIII deﬁciency. Mutations
in MTCYB, encoding cyt b, have been found linked to a wide range
of neuromuscular disorders, but also to Leber hereditary optic
neuropathy and tomultisystemdisorders (Gil Borlado et al., 2010).
Mutations inBCS1L, encoding an assembly factor of cIII,have been
associated with different clinical phenotypes such as GRACILE
(acronyn for Growth Retardation, Aminoaciduria, Cholestasis,
Iron overload, Lactic acidosis and Early death) syndrome, Bjorn-
stad syndrome, neonatal proximal tubulopathy, hepatopathy and
encephalopathy.
TTC19 is considered an assembly factor for cIII since its
absence has been associatedwith isolated cIII deﬁciency inTTC19-
mutant patients and ﬂy models (Ghezzi et al., 2011). TTC19 has
been shown to interact with cIII core subunits (UQCRC1 and
FIGURE 3 | Protein characterization and cIII assembly. (A)Western Blot
analysis of digitonin-treated ﬁbroblasts from patient (Pt) and controls (Ct1,
Ct2, Ct3) using antibodies againstTTC19 and SDHA, the latter used as
loading control. (B) First Dimension, Blue-Native Electrophoresis analysis of
ﬁbroblasts from patient (Pt) and control (Ct). An additional band was
detected (arrow) in the Pt lane using anti-complex III antibody (UQCRC1),
pointing out the presence of cIII-speciﬁc assembly intermediates.
Antibodies against complex I (NDUFS9) and complex II (SDHA) were used
as loading controls.
UQCRC2); accordingly cIII assembly intermediates containing
the same subunits were found in TTC19-mutant muscle. Here,
we conﬁrm the latter ﬁnding also in ﬁbroblasts lacking TTC19,
although in this specimen the biochemical defect was visibly less
pronounced than in muscle. These results suggest thatTTC19 may
play a role in an early phase of cIII assembly; alternatively, it could
act as a stabilizing factor at the end of the assembly pathway and
the observed cIII intermediates could be degradation products of
an unstable cIII.
Mutations in TTC19 have been associated with heteroge-
neous clinical presentations, including early (Ghezzi et al., 2011)
or late-onset ataxia (Nogueira et al., 2013; Morino et al., 2014),
cognitive impairment (Ghezzi et al., 2011), slowly progressive
developmental delay/regression due to necrotizing encephalomy-
opathy (Leigh syndrome; Atwal, 2013) and psychiatric symptoms
(Nogueira et al., 2013). MRI in these patients showed various
patterns, ranging from severe olivo–ponto–cerebellar atrophy to
cortical and/or cerebellar atrophy, basal ganglia and brainstem
necrosis.
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The patient here described presented extrapyramidal and cere-
bellar signs associated with cognitive impairment, symptoms
described in other infantile TTC19 patients (Ghezzi et al., 2011;
Atwal, 2013), but not the clear psychiatric involvement seen in
TTC19 late-onset patients (Ghezzi et al., 2011; Nogueira et al.,
2013) although behavioral and sleep abnormalities have been
reported in our case. These symptoms were not rapidly and easily
attributed to a speciﬁc syndrome, and also MRI patterns, charac-
terized by cerebellar hypoplasia and bilateral basal ganglia lesions,
displayed neuroradiological features seen in various mitochon-
drial encephalopathies, independently from the causative mutated
gene.
To reach the genetic diagnosis in such cases is often very difﬁ-
cult. In the last years a very important support has come from
new sequencing technologies such as WES. These approaches,
beyond the identiﬁcation of new disease genes, have allowed
identifying new disease phenotypes associated with mutations in
genes already known but usually associated with different clinical
features.
Although the availability of these new technologies has partly
overcome the need of selecting the candidate genes to be screened,
for the proper interpretation of the numerous variants identiﬁed
by such approach, the information on already known associa-
tion between clinical phenotypes and speciﬁc mutated genes are
still extremely important to reach a deﬁnite molecular diagnosis.
Moreover, for strict genotype–phenotype association the classi-
cal screening of single genes remains a time and cost-effective
option.
Probably new clinical presentations associated with TTC19
mutations will be identiﬁed in the near future, thanks to WES,
an unbiased approach particularly suitable for highly heteroge-
neous disorders with poor or still undeﬁned genotype–phenotype
correlations. Nevertheless, the biochemical cIII defect seems to
be a common and constant hallmark in TTC19 mutant patients,
highlighting the crucial role of TTC19 for proper cIII assembly or
stabilization.
Hence we suggest extending the TTC19 mutational screening,
by traditional or next-generation approaches, to all patients with
isolated cIII deﬁciency, independently from their phenotypes.
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